Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
25
datasets available to search
ShareScore release 0.9.0
Dataset results
25 results for “off-label”
Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)
ClinicalTrials.gov study NCT00419380. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe
ClinicalTrials.gov study NCT02240654. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury
ClinicalTrials.gov study NCT05204836. IPD Sharing: Not stated. Countries: 1. Publications: 45.
Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection
ClinicalTrials.gov study NCT02261662. IPD Sharing: Not stated. Countries: 1. Publications: 10.
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
ClinicalTrials.gov study NCT04578639. IPD Sharing: NO. Countries: 2. Publications: 0.
The bradykinin-2 receptor antagonist, icatibant, improves lung function in patients with SARS-CoV2 associated ARDS - First results of a prospective off-label use patient-related observational study.
<p>SARS-CoV2-associated adult respiratory distress syndrome (COVID19-ARDS) frequently leads to fatal respiratory failure in COVID19. Currently, there is no curative treatment option for severe COVID19-ARDS other than mechanical ventilation therapy and extracorporal membrane oxygenation (ECMO). We investigated whether modification of the kallikrein-kinin system in vivo attenuates the progression of SARS-CoV2-induced ARDS. The aim of the study was to investigate the effect of blockade of the B2R on the course of COVID19-ARDS. In an observational study including 53 COVID19-ARDS patients, patients received the bradykinin-2-receptor antagonist (B2RAg) icatibant. After icatibant substitution, respiratory rate in COVID19-ARDS reduced by a maximum of 32% (24.9/min to 16.8/min) with a concomitant reduction in oxygen substitution by 59% (6.1 LO<sub>2</sub>/min to 2.5 LO<sub>2</sub>/min). The data show that the use of icatibant in the early phase of COVID19-ARDS is suitable to stabilize pulmonary gas exchange. Furthermore, early icatibant substitution seems to be able to reduce the rate of necessary invasive ventilation in COVID19-ARDS. Observational data suggest that inhibition of bradykinin signalling leads to stabilization of lung function in SARS-CoV2-associated ARDS. Further prospective placebo-controlled studies are needed to investigate the impact of the kallikrein-kinin system on the development of COVID19-ARDS in vivo.</p>
Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy
ClinicalTrials.gov study NCT00344617. IPD Sharing: Not stated. Countries: 0. Publications: 2.
The bradykinin-2 receptor antagonist, icatibant, improves lung function in patients with SARS-CoV2 associated ARDS - First results of a prospective off-label use patient-related observational study.
Open the record for dataset details and reuse information.
Figure 3 from: Drenska M, Naseva E, Getov IN (2019) The knowledge and experience with the off-label use – results of a survey. Pharmacia 66(4): 217-221. https://doi.org/10.3897/pharmacia.66.e46687
Figure 3 The main off-label medical areas.
Figure 2 from: Drenska M, Naseva E, Getov IN (2019) The knowledge and experience with the off-label use – results of a survey. Pharmacia 66(4): 217-221. https://doi.org/10.3897/pharmacia.66.e46687
Figure 2 The main reasons for off-label use.
Figure 1 from: Drenska M, Naseva E, Getov IN (2019) The knowledge and experience with the off-label use – results of a survey. Pharmacia 66(4): 217-221. https://doi.org/10.3897/pharmacia.66.e46687
Figure 1 Distribution of participants by their medical specialty.
Figure 2 from: Drenska M, Elitova S, Grigorova V, Naseva E, Getov I (2019) Analysis of primary outpatient data for off-label use of medicines in neurology. Pharmacia 66(4): 165-170. https://doi.org/10.3897/pharmacia.66.e36620
Figure 2 Type of off-label use.
Figure 1 from: Drenska M, Elitova S, Grigorova V, Naseva E, Getov I (2019) Analysis of primary outpatient data for off-label use of medicines in neurology. Pharmacia 66(4): 165-170. https://doi.org/10.3897/pharmacia.66.e36620
Figure 1 Off-label use with regard to patients and prescriptions.
Evaluating Off-label Use of Direct Oral Anticoagulants (DOACs) in Hypercoagulable States
ClinicalTrials.gov study NCT04565977. IPD Sharing: NO. Countries: 1. Publications: 0.
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 1
ClinicalTrials.gov study NCT06004830. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The RITAI Cohort: An Observational Study on Rituximab Off-label Use for Auto-immune Disorders
ClinicalTrials.gov study NCT00960713. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Relationship Between Adverse Drug Reactions and Unlicensed/ Off-label Drug Use in Hospitalized Children
ClinicalTrials.gov study NCT02852590. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Cost of Off-label Antibiotics in Osteoarticular Infections
ClinicalTrials.gov study NCT03335592. IPD Sharing: NO. Countries: 1. Publications: 0.
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide
ClinicalTrials.gov study NCT07040592. IPD Sharing: NO. Countries: 1. Publications: 0.
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
ClinicalTrials.gov study NCT06006143. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.